Amphastar Pharmaceuticals, Novavax, and Organon Shares Skyrocket, What You Need To Know
OGN Q4 Deep Dive: Margin Compression and U.S. Headwinds Shape 2026 Outlook
Organon (NYSE:OGN) Reports Q4 CY2025 In Line With Expectations
Full year 2025 revenue of $6.2 billion, down 3% on both an as-reported basis and at constant currency Full year 2025 diluted earnings per share of $0.72 and non-GAAP Adjusted diluted...
2 Healthcare Stocks with Promising Prospects and 1 We Brush Off
Organon (NYSE: OGN), a global healthcare company with a primary focus on women’s health, will release its fourth quarter and full year 2025 financial results on February 12, 2026, prior to the company’s...
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today the successful closing of the sale of its JADA ...